Jounce Therapeutics (NASDAQ: AGEN) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, risk, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Jounce Therapeutics and Agenus, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jounce Therapeutics 0 3 3 0 2.50
Agenus 0 0 0 0 N/A

Jounce Therapeutics currently has a consensus price target of $13.20, indicating a potential upside of 76.23%. Given Jounce Therapeutics’ higher possible upside, research analysts clearly believe Jounce Therapeutics is more favorable than Agenus.

Risk and Volatility

Jounce Therapeutics has a beta of 5.17, meaning that its share price is 417% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.


This table compares Jounce Therapeutics and Agenus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Jounce Therapeutics -50.54% -23.27% -11.42%
Agenus -281.49% N/A -102.16%

Institutional and Insider Ownership

91.8% of Jounce Therapeutics shares are owned by institutional investors. Comparatively, 45.5% of Agenus shares are owned by institutional investors. 44.0% of Jounce Therapeutics shares are owned by insiders. Comparatively, 6.4% of Agenus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Jounce Therapeutics and Agenus’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Jounce Therapeutics $71.64 million 3.41 -$16.44 million ($0.57) -13.14
Agenus $42.88 million 4.41 -$120.69 million ($1.23) -1.36

Jounce Therapeutics has higher revenue and earnings than Agenus. Jounce Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.


Jounce Therapeutics beats Agenus on 10 of the 13 factors compared between the two stocks.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Agenus Company Profile

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with's FREE daily email newsletter.